



(11) **EP 2 882 819 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C09D 171/00 ^(2006.01) **C09D 163/02** ^(2006.01)
B05D 7/14 ^(2006.01) **B65D 1/12** ^(2006.01)
C08G 65/26 ^(2006.01) **B65D 25/14** ^(2006.01)
B65D 81/34 ^(2006.01) **C09D 171/12** ^(2006.01)

(48) Corrigendum issued on:
19.12.2018 Bulletin 2018/51

(86) International application number:
PCT/US2013/054132

(45) Date of publication and mention
of the grant of the patent:
03.10.2018 Bulletin 2018/40

(87) International publication number:
WO 2014/025997 (13.02.2014 Gazette 2014/07)

(21) Application number: **13827304.0**

(22) Date of filing: **08.08.2013**

(54) **COMPOSITIONS FOR CONTAINERS AND OTHER ARTICLES AND METHODS OF USING SAME**
GEGENSTÄNDE UND VERFAHREN FÜR DEREN VERWENDUNG
COMPOSITIONS POUR DES RÉCIPIENTS ET D'AUTRES ARTICLES ET LEURS PROCÉDÉS
D'UTILISATION

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

• **VON MAIER, Mark, S.**
Minneapolis, MN 55440-1461 (US)

(30) Priority: **09.08.2012 US 201261681434 P**

(74) Representative: **Vossius & Partner**
Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München (DE)

(43) Date of publication of application:
17.06.2015 Bulletin 2015/25

(56) References cited:
WO-A1-95/26997 WO-A2-2011/130671
WO-A2-2011/130671 JP-A- H07 138 502
JP-B2- 3 484 546 US-A1- 2005 215 670
US-A1- 2007 087 146 US-A1- 2007 087 146

(60) Divisional application:
18197657.2

(73) Proprietor: **SWIMC LLC**
Cleveland, Ohio 44115 (US)

• **"TEST METHOD NOMINATION: MCF-7 CELL**
PROLIFERATION ASSAY OF ESTROGENIC
ACTIVITY This nomination application includes
no confidential information. TABLE OF
CONTENTS Page # I Executive Summary 2 1.0
Introduction and Rationale for the Proposed Test
Method 6 2.0 Test Method Protocol Components
16 3.0 Subs", , 1 June 2007 (2007-06-01),
XP055258155, Retrieved from the Internet:
URL:[http://ntp.niehs.nih.gov/iccvam/method](http://ntp.niehs.nih.gov/iccvam/method/s/endocrine/endodocs/submdoc.pdf)
s/endocrine/endodocs/submdoc.pdf [retrieved
on 2016-03-14]

(72) Inventors:
• **NIEDERST, Jeffrey**
Minneapolis, MN 55440-1461 (US)
• **EVANS, Richard, H.**
Minneapolis, MN 55440-1461 (US)
• **O'BRIEN, Robert, M.**
Minneapolis, MN 55440-1461 (US)
• **ROMAGNOLI, Kevin**
Minneapolis, MN 55440-1461 (US)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 882 819 B8

- **SHIGEYUKI KITAMURA ET AL: "Comparative Study of the Endocrine-Disrupting Activity of Bisphenol A and 19 Related Compounds", TOXICOLOGICAL SCIENCES, ACADEMIC PRESS, vol. 84, no. 2, 1 February 2005 (2005-02-01), pages 249-259, XP002657107, ISSN: 1096-6080, DOI: 10.1093/TOXSCI/KFI074**